子宫切除术在妊娠滋养细胞肿瘤管理中的附加价值
本研究基于荷兰全国数据库,回顾性分析了1977年至2012年间109例接受子宫切除术的妊娠滋养细胞肿瘤(GTN)患者,占全部注册GTN患者的16.5%。多数患者为低危(74.3%)、葡萄胎后GTN(73.5%)及病变局限于子宫(65.1%)。局部病变患者子宫切除后完全缓解率66.2%,转移性病变患者为15.8%。对于局部病变,初次子宫切除术较匹配对照组治疗时间显著缩短(平均3.2周 vs 8.0周,p=0.01),化疗周期数更少(平均1.5 vs 5.8,p<0.01)。
要点
- 子宫切除术是部分GTN患者的管理组成,全国队列中占16.5%。
- 局部病变患者子宫切除后完全缓解率66.2%,转移性病变患者为15.8%。
- 局部病变初次子宫切除术较对照组治疗时间更短、化疗周期更少。
核心结论
- 在选定病例中,子宫切除术可能是减少或消除肿瘤负荷的有效手段。
- 初次子宫切除术主要应考虑用于年龄较大、病变局限且无生育要求的患者。
- 化疗耐药患者可能从附加子宫切除术中获益,尤其是病变局限时。
- 对于广泛转移性疾病,子宫切除术的获益在于去除化疗耐药肿瘤负荷并随后影响生存。
研究设计与样本
- 全国性队列研究,基于荷兰国家数据库回顾性识别1977年至2012年间诊断为GTN并接受子宫切除术的患者,共109例(占全部注册GTN患者的16.5%)。
主要发现
- 109例患者中,低危疾病占74.3%,葡萄胎后GTN占73.5%,病变局限于子宫占65.1%。
- 子宫切除术后,局部病变患者完全缓解率为66.2%,转移性病变患者为15.8%。
- 局部病变患者中,初次子宫切除术组治疗时间平均3.2周,匹配对照组平均8.0周(p=0.01)。
- 局部病变患者中,初次子宫切除术组化疗周期数平均1.5,匹配对照组平均5.8(p<0.01)。
临床怎么用
- 作者认为,在选定病例中子宫切除术可能是减少或消除肿瘤负荷的有效手段。
- 作者建议,初次子宫切除术主要应考虑用于年龄较大、病变局限且无生育要求的患者。
- 作者认为,化疗耐药患者可能从附加子宫切除术中获益,尤其是病变局限时。
- 作者认为,对于广泛转移性疾病,子宫切除术的获益在于去除化疗耐药肿瘤负荷并随后影响生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the undoubted effectiveness of chemotherapeutic treatment in gestational trophoblastic neoplasia (GTN), problems related to toxicity of chemotherapy and chemo-resistant disease have led to reconsideration of the use of hysterectomy. Aim of the present study was to evaluate indications for and outcome of hysterectomy in patients with GTN in a nation-wide cohort. METHODS: Between 1977 and 2012, we identified all patients diagnosed with GTN and treated with hysterectomy from the Dutch national databases. Demographics, clinical characteristics and follow-up were recorded retrospectively. RESULTS: One hundred and nine patients (16.5% of all registered patients with GTN) underwent hysterectomy as part of their management for GTN. The majority of patients was classified as low-risk disease (74.3%), post-molar GTN (73.5%) and disease confined to the uterus (65.1%). After hysterectomy, complete remission was achieved in 66.2% of patients with localized disease and in 15.8% of patients with metastatic disease. For patients with localized disease, treated with primary hysterectomy, treatment duration was significantly shorter (mean 3.2weeks and 8.0weeks respectively, p=0.01) with lower number of administered chemotherapy cycles (mean 1.5 and 5.8 respectively, p<0.01) than patients in a matched control group. CONCLUSION: In selected cases, a hysterectomy may be an effective means to either reduce or eliminate tumor bulk. Primary hysterectomy should mainly be considered in older patients with localized disease and no desire to preserve fertility, whereas patients with chemotherapy-resistant disease may benefit from additional hysterectomy, especially when disease is localized. For patients with widespread metastatic disease, the benefit of hysterectomy lies in the removal of chemotherapy-resistant tumor bulk with subsequent effect on survival.
引用
- Eysbouts YK, Massuger LFAG, IntHout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol. 2017. PMID: 28390821. doi:10.1016/j.ygyno.2017.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。